In Reply Dr Broder and Mr Ortendahl critique our definition of value-based pricing as relying on cost-effectiveness analyses from ICER. That is not correct; we only mentioned the work of ICER as an example of a value-based price. They also suggest that we argued for the use of cost-effectiveness analyses and QALYs as the only measure of benefit. We did not say that, nor, to our knowledge, does ICER. Moreover, our work on tools such as the DrugAbacus explicitly acknowledges the multidimensional nature of value assessment, considering, for example, rarity of disease, unmet need, and prognosis.1
Kaltenboeck A, Bach PB. Defining Value-Based Pricing of Drugs—Reply. JAMA. 2018;320(16):1710–1711. doi:10.1001/jama.2018.11820
Customize your JAMA Network experience by selecting one or more topics from the list below.